Novartis AG — Director's Dealing 2020

Jul 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akouos, Inc. (AKUS)
CIK: 0001722271
Period of Report: 2020-06-30

Reporting Person: Novartis Bioventures Ltd (Former 10% Owner)
Reporting Person: NOVARTIS AG (Former 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-30	Common Stock	C	856262	—	Acquired	856262	Indirect
2020-06-30	Common Stock	C	199996	—	Acquired	1056258	Indirect
2020-06-30	Common Stock	P	125000	$17.00	Acquired	1181258	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-30	Series A Preferred Stock	$	C	856262	Disposed		Common Stock (856262)	Indirect
2020-06-30	Series B Preferred Stock	$	C	199996	Disposed		Common Stock (199996)	Indirect

Footnotes

F1: On June 30, 2020, the Series A Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.

F3: On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.